Results 41 to 50 of about 108,588 (220)

Visceral Leishmaniasis

Infectious Disease Clinics of North America, 2012
Visceral leishmaniasis (VL) is a vector-borne parasitic disease targeting tissue macrophages. It is among the most neglected infectious diseases. Classical manifestations of VL include chronic fever, hepatosplenomegaly, and pancytopenia. Most cases can be detected through serologic and molecular testing.
van Griensven, J., Diro, E.
openaire   +3 more sources

Advances in leishmaniasis.

, 2005
Governed by parasite and host factors and immunoinflammatory responses, the clinical spectrum of leishmaniasis encompasses subclinical (inapparent), localised (skin lesions), and disseminated infection (cutaneous, mucosal, or visceral).
Berman, Jonathan D, Davies, Clive R, Murray, Henry W, Saravia, Nancy G   +3 more
core   +1 more source

Low castes have poor access to visceral leishmaniasis treatment in Bihar, India [PDF]

, 2012
Objectives  Bihar, the poorest state in India, concentrates most of the visceral leishmaniasis (VL) cases in the country. A large proportion of the poor rural communities where VL is endemic are marginalized by their socio-economic status, intrinsically ...
Alvar, Babu, Barratt, Boelaert, Cerf, Collin, de Onis, Dedet, Desjeux, Dye, Hasker, Heymann, India., G.o, Mondal, Ostyn, Ranjan, Sinha, Thakur, Van de Poel, WHO, WHO, WHO, WHO/UNICEF   +22 more
core   +2 more sources

Safety, tolerability and pharmacokinetics of DNDI‐6148, a novel agent for leishmaniasis: A randomized, controlled, single ascending dose study in healthy participants

British Journal of Clinical Pharmacology, EarlyView.
Aim The benzoxaborole derivative DNDI‐6148 is an antiparasitic agent with activity against multiple Leishmania protozoan species, including L. infantum and L. donovani, which cause visceral leishmaniasis. We investigated the safety, tolerability and pharmacokinetics of single oral doses of DNDI‐6148 in a randomized, parallel‐group, placebo‐controlled ...
Jean‐Yves Gillon, Sophie Delhomme, Delphine Launay, Séverine Blesson, Stéphanie Braillard, Pegah Maghdooni, Frauke Assmus, Richard Hoglund, Joel Tarning, Sabrina Loyau, Byron Arana, Mathilde Latreille‐Barbier, Yves Donazzolo   +12 more
wiley   +1 more source

The synergistic anti-leishmanial effect of photodynamic therapy employing chemotherapy-mediated nanocomposites

Scientific Reports
Cutaneous leishmaniasis (CL) presents a significant therapeutic challenge due to limitations of current treatments like meglumine antimoniate (MAT), including drug resistance and adverse side effects. Photodynamic therapy (PDT) has emerged as a promising,
Elahe Molaakbari, Ahmad Khosravi, Ehsan Salarkia, Iraj Sharifi, Alireza Keyhani, Mehdi Bamorovat, Mohammad Zarif, Fatemeh Sharifi   +7 more
doaj   +1 more source

A Case Report of a Successful Allergen Immunotherapy with Candida Albicans in Patient with Sever Atopic Dermatitis Sensitive to Candida Albicans [PDF]

Patient Safety and Quality Improvement Journal, 2019
Introduction: Atopic dermatitis (AD) is an inflammatory, chronic, relapsing, itchy skin disease with an immunologic basis. This disease is associated with itchy skin lesions (pruritus), dry skin (xerosis) and plaques of eczema. The role of aeroallergens,
Farahzad Jabbari Azad, Payam Payandeh, Pouran Layegh, Javad Fadaee   +3 more
doaj   +1 more source

Declining Visceral Leishmaniasis in Malta [PDF]

, 2008
Aims: To study visceral leishmaniasis (VL) trends in Malta. Methods: Analysis of epidemiological and clinical trends, a veterinary questionnaire and questioning a canine laboratory testing facility.
Grech, Victor E., Vella, Cecil
core  

Cell membrane‐coated nanoparticles for dermatological diseases

VIEW, EarlyView.
Skin disorders are challenging to treat due to complex barrier functions and limited conventional therapies. Biomimetic cell membrane‐coated nanoparticles (CM‐NPs) offer a superior nanomedicine approach by evading immune detection and enabling precise targeting.
Shuaijun Zou, Baojie Zhang, Yuanjie Zhu
wiley   +1 more source

Cutaneous Leishmaniasis

The Moldovan Medical Journal, 2018
Background: Leishmaniasis is a disease caused by parasites of the Leishmania type. Cutaneous leishmaniasis (CL) is a neglected worldwide, zoonotic, vector-borne, tropical disease. The clinical spectrum of leishmaniasis ranges from a self-resolving cutaneous ulcer to a mutilating mucocutaneous disease and even to a lethal systemic illness.
Placinta, Gheorghe, Pantea, Victor, Cebotarescu, Valentin, Cojuhari, Lilia, Paveliuc, Petru, Musteata, Tatiana, Panasiuc, Alexandru, Lungu, Victoria, Simonov, Ludmila   +8 more
openaire   +3 more sources

Risk factors for visceral leishmaniasis in a new epidemic site in Amhara Region, Ethiopia [PDF]

, 2009
We conducted a case-control study to evaluate risk factors for visceral leishmaniasis during an epidemic in a previously unaffected district of Ethiopia. We also collected blood and bone marrow specimens from dogs in the outbreak villages.
Alvar, Jorge, Aparicio, Pilar, Argaw, Daniel, Bashaye, Seife, Bern, Caryn, Cañavate, Carmen, Chicharro, Carmen, Herrero, Merce, Mulugeta, Abate, Nieto, Javier, Nombela, Nohelly, Vélez, Iván Darío   +11 more
core   +1 more source